First-line chemotherapy for NSCLC: an overview of relevant trials
First-line chemotherapy for NSCLC: an overview of relevant trials
复制标题
DOI：
10.1016/s0169-5002(02)00394-x
复制
发表时间：
2002-12-01
期刊：
影响因子：
5.3
通讯作者：
Langer, C
中科院分区：
文献类型：
--
作者：
Belani, CP;Langer, C
在晚期非小细胞肺癌(NSCLC)中，与单独进行最好的支持性治疗相比，吉西他滨单一疗法改善了生活质量，而单药紫杉烷和长春瑞滨也提高了生存率。与单药顺铂相比，以铂为基础的联合用药在应答率、进展时间和存活率方面都有好处。随着新药物组合的引入，在合作组试验中可以看到10-20%的两年存活率。直到最近，接受随机比较的各种二联体似乎取得了相似的应答率和存活率，尽管毒性因所用药物的选择而有很大差异。然而，迄今在晚期非小细胞肺癌中进行的最大规模的试验Tax 326研究表明，多西紫杉醇和顺铂的联合应用优于长春瑞滨和顺铂。含铂和不含铂的组合的对照试验尚未证明其中一种优于另一种。进一步提高存活率的希望集中在细胞毒剂与新型分子靶向药物的结合上，如抗血管生成药物和EGFR抑制剂。(C)2002爱思唯尔科学爱尔兰有限公司。保留所有权利。
In advanced non-small cell lung cancer (NSCLC), monotherapy with gemcitabine improves quality of life when compared to best supportive care alone, while single-agent taxanes and vinorelbine also improve survival. Platinum-based combinations achieve benefits in response rate, time to progression and survival compared to single-agent cisplatin. With the introduction of combinations of newer agents, 2-year survival rates of 10-20% are being seen in co-operative group trials. Until recently, the various doublets that have been subjected to randomized comparison appear to have achieved similar rates of response and survival, though toxicities differ considerably depending on the choice of drugs used. However, study TAX 326, the largest trial yet conducted in advanced NSCLC, has now demonstrated that the combination of docetaxel with cisplatin is superior to that of vinorelbine and cisplatin. Controlled trials of platinum-containing vs. non-platinum combinations have yet to demonstrate any superiority of one over the other. Hopes for further improvement in survival are focused on the combination of cytotoxic agents with novel molecularly-targeted drugs such as the anti-angiogenics and EGFR inhibitors. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.